Copenhagen, Denmark – Medicollect today announced its expansion into UK, increasing its acceptance footprint across the continent. The addition of the British network extends the company’s reach to 3, 4 million diabetes patients.
According to a report produced for the drug company Novartis clinical trials in the United Kingdom cost significantly more than in other European countries, in large because of poor rates of recruitment (source).
“This means that there is an increasing need for innovative and reliable solutions that address market needs,” says Torben Lind, COO at Medicollect. “Our investment in UK will secure that test patients for clinical diabetes trials in United Kingdom will be provided at the same fast, safe and reliable way that Medicollect has serviced the Scandinavian market.
Through collaborating with diabetes stakeholders in UK and Denmark, Medicollect is directly contributing to bringing medical innovation to patients faster and support United Kingdom’s transformation to once more being a strong center for clinical trials.
Want to know more?
Contact Torben Lind